As FN is upregulated in many cancers, it has been exploited primarily in cancer imaging and for the targeted delivery of therapies; numerous antibodies, peptides, and modified ligands have been used to deliver isotopes, chemotherapeutics, and immunomodulators to tumours in pre-clinical models (reviewed [115,116]). Here, FN1 is linked to cancer.